UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report: February 10, 2014
(Date of earliest event reported)
ImmuCell Corporation
(Exact name of registrant as specified in its charter)
|
DE
(State or other jurisdiction
of incorporation)
|
001-12934
(Commission File Number)
|
01-0382980
(IRS Employer
Identification Number)
|
| |
|
56 Evergreen Drive
Portland, Maine
(Address of principal executive offices)
|
|
04103
(Zip Code)
|
207-878-2770
(Registrant's telephone number, including area code)
Not Applicable
(Former Name or Former Address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 –Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
On February 10, 2014, Dr. William H. Maxwell gave notice of his resignation from his position on the Company’s Board of Directors effective immediately in order to pursue other interests.
Dr. Maxwell was thanked and congratulated for his dedicated service to the Company since 1986.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: February 12, 2014 |
IMMUCELL CORPORATION |
| |
|
| |
By: /s/Michael F Brigham |
| |
Michael F. Brigham
|
| |
President and CEO
|